Search

Your search keyword '"David Ames"' showing total 300 results
Start Over Author "David Ames" Publisher wiley
300 results on '"David Ames"'

1. Rates of age‐ and amyloid β‐associated cortical atrophy in older adults with superior memory performance

Author

Christa Dang, Nawaf Yassi, Karra D. Harrington, Ying Xia, Yen Ying Lim, David Ames, Simon M. Laws, Martha Hickey, Stephanie Rainey‐Smith, Hamid R. Sohrabi, James D. Doecke, Jurgen Fripp, Olivier Salvado, Peter J. Snyder, Michael Weinborn, Victor L. Villemagne, Christopher C. Rowe, Colin L. Masters, Paul Maruff, AIBL Research Group, Brian Chambers, Edmond Chiu, Roger Clarnette, David Darby, Mary Davison, John Drago, Peter Drysdale, Jacqueline Gilbert, Kwang Lim, Nicola Lautenschlager, Dina LoGiudice, Peter McCardle, Steve McFarlane, Alastair Mander, John Merory, Daniel O'Connor, Ron Scholes, Mathew Samuel, Darshan Trivedi, and Michael Woodward

Subjects
Aging, β‐amyloid, Alzheimer's disease, Neurodegeneration, Memory, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Introduction Superior cognitive performance in older adults may reflect underlying resistance to age‐associated neurodegeneration. While elevated amyloid β (Aβ) deposition (Aβ+) has been associated with increased cortical atrophy, it remains unknown whether “SuperAgers” may be protected from Aβ‐associated neurodegeneration. Methods Neuropsychologically defined SuperAgers (n = 172) and cognitively normal for age (n = 172) older adults from the Australian Imaging, Biomarkers and Lifestyle study were case matched. Rates of cortical atrophy over 8 years were examined by SuperAger classification and Aβ status. Results Of the case‐matched SuperAgers and cognitively normal for age older adults, 40.7% and 40.1%, respectively, were Aβ+. Rates of age‐ and Aβ‐associated atrophy did not differ between the groups on any measure. Aβ− individuals displayed the slowest rates of atrophy. Discussion Maintenance of superior memory in late life does not reflect resistance to age‐ or Aβ‐associated atrophy. However, those individuals who reached old age without cognitive impairment nor elevated Aβ deposition (i.e. Aβ−) displayed reduced rates of cortical atrophy.

Published
2019
Full Text
View/download PDF

2. Learning deficit in cognitively normal APOE ε4 carriers with LOW β‐amyloid

Author

Yen Ying Lim, Jenalle E. Baker, Andrea Mills, Loren Bruns Jr, Christopher Fowler, Jurgen Fripp, Stephanie R. Rainey‐Smith, David Ames, Colin L Masters, and Paul Maruff

Subjects
Alzheimer's disease, amyloid, apolipoprotein E, learning, memory, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Introduction In cognitively normal (CN) adults, increased rates of amyloid beta (Aβ) accumulation can be detected in low Aβ (Aβ–) apolipoprotein E (APOE) ε4 carriers. We aimed to determine the effect of ε4 on the ability to benefit from experience (ie, learn) in Aβ– CNs. Methods Aβ– CNs (n = 333) underwent episodic memory assessments every 18 months for 108 months. A subset (n = 48) completed the Online Repeatable Cognitive Assessment‐Language Learning Test (ORCA‐LLT) over 6 days. Results Aβ– ε4 carriers showed significantly lower rates of improvement on episodic memory over 108 months compared to non‐carriers (d = 0.3). Rates of learning on the ORCA‐LLT were significantly slower in Aβ– ε4 carriers compared to non‐carriers (d = 1.2). Discussion In Aβ– CNs, ε4 is associated with a reduced ability to benefit from experience. This manifested as reduced practice effects (small to moderate in magnitude) over 108 months on the episodic memory composite, and a learning deficit (large in magnitude) over 6 days on the ORCA‐LLT. Alzheimer's disease (AD)–related cognitive abnormalities can manifest before preclinical AD thresholds.

Published
2021
Full Text
View/download PDF

3. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease

Author

Kunal Dhiman, Veer Bala Gupta, Victor L. Villemagne, Dhamidhu Eratne, Petra L. Graham, Christopher Fowler, Pierrick Bourgeat, Qiao‐Xin Li, Steven Collins, Ashley I. Bush, Christopher C. Rowe, Colin L. Masters, David Ames, Eugene Hone, Kaj Blennow, Henrik Zetterberg, and Ralph N. Martins

Subjects
amyloid, biomarker, dementia, diagnosis, ELISA, neurodegeneration, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Introduction This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation. Methods CSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). Results CSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; P < .001), and in mild cognitive impairment (MCI) compared to HC (P = .008 NfL; P < .001 NfL/Aβ42). CSF NfL and NfL/Aβ42 differentiated AD from HC with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/Aβ42 predicted cortical amyloid load, brain atrophy, and cognition. Discussion CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology.

Published
2020
Full Text
View/download PDF

4. Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness

Author

Karra D. Harrington, Yen Ying Lim, David Ames, Jason Hassenstab, Simon M. Laws, Ralph N. Martins, Stephanie Rainey‐Smith, Joanne Robertson, Christopher C. Rowe, Olivier Salvado, Vincent Doré, Victor L. Villemagne, Peter J. Snyder, Colin L. Masters, Paul Maruff, and AIBL Research Group

Subjects
Alzheimer disease, Amyloid, Cognitive aging, Normal aging, Memory, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Introduction High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aβ−) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aβ− group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.

Published
2017
Full Text
View/download PDF

5. Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort

Author

Veer Bala Gupta, Eugene Hone, Steve Pedrini, James Doecke, Sid O'Bryant, Ian James, Ashley I. Bush, Christopher C. Rowe, Victor L. Villemagne, David Ames, Colin L. Masters, Ralph N. Martins, and AIBL Research Group

Subjects
Blood, Biomarkers, Alzheimer's disease, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Introduction A blood‐based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P = .0003) and chemokine‐309 (I‐309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P = .0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I‐309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.

Published
2017
Full Text
View/download PDF

6. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging

Author

Veer Bala Gupta, James D. Doecke, Eugene Hone, Steve Pedrini, Simon M. Laws, Madhav Thambisetty, Ashley I. Bush, Christopher C. Rowe, Victor L. Villemagne, David Ames, Colin L. Masters, Stuart Lance Macaulay, Alan Rembach, Stephanie R. Rainey‐Smith, Ralph N. Martins, and AIBL Research Group

Subjects
Biomarkers, Apolipoprotein J, Plasma, Brain amyloid beta, Hippocampus volume, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Introduction For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD. Methods Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele status, mini‐mental state examination score, plasma amyloid beta (Aβ), neocortical Aβ burden (as measured by Pittsburgh compound B‐positron emission tomography), and total adjusted hippocampus volume. Results ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as compared with healthy controls (HC; P

Published
2016
Full Text
View/download PDF

7. The relationship between objective physical activity and change in cognitive function

Author

Kelsey R. Sewell, Stephanie R. Rainey‐Smith, Jeremiah Peiffer, Hamid R. Sohrabi, Kevin Taddei, David Ames, Paul Maruff, Colin L. Masters, Christopher C. Rowe, Ralph N. Martins, Kirk I. Erickson, and Belinda M. Brown

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2023

8. Plasma glial fibrillary acidic protein is associated with reactive astrogliosis assessed via 18 F‐SMBT‐1 PET

Author

Pratishtha Chatterjee, Vincent Dore, Steve Pedrini, Natasha Krishnadas, Rohith N Thota, Pierrick Bourgeat, Stephanie Rainey‐Smith, Samantha C Burnham, Christopher Fowler, Kevin Taddei, Rachel S Mulligan, David Ames, Colin L. Masters, Jurgen Fripp, Christopher Rowe, Ralph N Martins, and Victor L Villemagne

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022

9. Objectively measured physical activity and cognition in cognitively normal older adults: A longitudinal analysis of the Australian Imaging Biomarkers and Lifestyle (AIBL) study

Author

Kelsey R Sewell, Stephanie Rainey‐Smith, Victor L Villemagne, Jeremiah J Peiffer, Hamid R Sohrabi, Kevin Taddei, David Ames, Paul Maruff, Simon M Laws, Colin L. Masters, Christopher Rowe, Ralph N Martins, Kirk I. Erickson, and Belinda M Brown

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022

11. Assessment of the DTI‐ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia

Author

Elaine Lui, Roland Bammer, Nicola T. Lautenschlager, David Ames, Charles B Malpas, Vijay K. Venkatraman, Lucy Vivash, Elizabeth V. Cyarto, Dennis Velakoulis, Christopher Steward, Patricia Desmond, Colin L. Masters, Terence J. O'Brien, and Kathryn A. Ellis

Subjects
Male, medicine.medical_specialty, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Cognition, 0302 clinical medicine, Neuroimaging, Alzheimer Disease, Internal medicine, medicine, Humans, Effective diffusion coefficient, Dementia, Cognitive Dysfunction, Radiology, Nuclear Medicine and imaging, Perivascular space, Aged, Aged, 80 and over, business.industry, Brain, Middle Aged, medicine.disease, Diffusion Tensor Imaging, medicine.anatomical_structure, Susceptibility weighted imaging, Cardiology, Female, Glymphatic system, Neurology (clinical), Alzheimer's disease, business, Glymphatic System, 030217 neurology & neurosurgery, Diffusion MRI
Abstract

BACKGROUND AND PURPOSE: Recently, there has been growing interest in the glymphatic system (the functional waste clearance pathway for the central nervous system and its role in flushing solutes (such as amyloid s and tau), metabolic, and other cellular waste products in the brain. Herein, we investigate a recent potential biomarker for glymphatic activity (the diffusion tensor imaging along the perivascular space [DTI-ALPS] parameter) using diffusion MRI imaging in an elderly cohort comprising 10 cognitively normal, 10 mild cognitive impairment (MCI), and 16 Alzheimer's disease (AD). METHODS: All 36 participants imaged on a Siemens 3.0T Tim Trio. Single-SE diffusion weighted Echo-planar imaging scans were acquired as well as T1 magnetization prepared rapid gradient echo, T2 axial, and susceptibility weighted imaging. Three millimeter regions of interest were drawn in the projection and association fibers adjacent to the medullary veins at the level of the lateral ventricle. The DTI-ALPS parameter was calculated in these regions and correlated with cognitive status, Mini-Mental State Examination (MMSE), and ADASCog11 measures. RESULTS: Significant correlations were found between DTI-ALPS and MMSE and ADASCog11 in the right hemisphere adjusting for age, sex, and APoE e4 status. Significant differences were also found in the right DTI-ALPS indices between cognitively normal and AD groups (P < .026) and MCI groups (P < .025) in a univariate general linear model corrected for age, sex, and APoE e4. Significant differences in apparent diffusion coefficient between cognitively normal and AD groups were found in the right projection fibers (P = .028). CONCLUSION: Further work is needed to determine the utility of DTI-ALPS index in larger elderly cohorts and whether it measures glymphatic activity.

Published
2021

12. Dementia and caregiver burden: A three‐year longitudinal study

Author

David Ames, Michael H. Connors, Katrin Seeher, Armando Teixeira-Pinto, Henry Brodaty, and Michael M Woodward

Subjects
Male, Gerontology, Longitudinal study, 03 medical and health sciences, 0302 clinical medicine, Cost of Illness, medicine, Humans, Dementia, Longitudinal Studies, Functional ability, Vascular dementia, Depression (differential diagnoses), Aged, Aged, 80 and over, 030214 geriatrics, Family caregivers, business.industry, Australia, Caregiver burden, medicine.disease, Mental health, Psychiatry and Mental health, Caregivers, Female, Geriatrics and Gerontology, business
Abstract

Objectives Dementia, with its progressive cognitive and functional decline and associated neuropsychiatric symptoms, places a large burden on caregivers. While frequently studied, longitudinal findings about the overall trajectory of burden are mixed. The study sought to characterize caregiver burden over a 3-year period and identify predictors of this burden. Methods Seven-hundred-and-eighty-one patients with dementia were recruited from nine memory clinics around Australia. Measures of caregiver burden, cognition, function, and neuropsychiatric symptoms were completed with patients and their caregivers at regular intervals over a 3-year period. Patients' level of services and medication use were also recorded. Results Of the 720 patients with measures of caregiver burden at baseline, 47.4% of caregivers had clinically significant levels of burden. This proportion increased over time, with 56.8% affected at 3 years. Overall levels of burden increased for caregivers of patients without services, though did not change for caregivers of patients receiving services or residential care after controlling for other variables. Patient characteristics-including greater neuropsychiatric symptoms, lower functional ability, fewer medications, lack of driving ability-and female sex of caregivers were associated with greater burden. Conclusions High levels of caregiver burden are present in a large proportion of caregivers of people with dementia and this increases over time for those without services. Clinical characteristics of patients (including neuropsychiatric symptoms, function, overall health, driving status), level of services, and caregiver sex appear to be the best predictors of this burden. These characteristics may help identify caregivers at greater risk of burden to target for intervention.

Published
2019

13. How lifestyle shapes the brain: Associations between physical activity, sleep, beta‐amyloid and cognitive function in older adults

Author

Kelsey R Sewell, Stephanie R Rainey‐Smith, Victor LL Villemagne, Jeremiah J Peiffer, Hamid R Sohrabi, Kevin Taddei, David Ames, Paul T Maruff, Simon M Laws, Colin L Masters, Christopher C Rowe, Ralph N Martins, Kirk I. Erickson, and Belinda M Brown

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2021

14. Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimer’s disease

Author

Tingting Wang, Kevin Huynh, Corey Giles, Wei Ling Florence Lim, Thy Duong, Natalie A. Mellett, Alexander Smith, Gavriel Olshansky, Brian G. Drew, Gemma Cadby, Phillip E. Melton, Joseph Hung, John Beilby, Gerald F. Watts, Pratishtha Chatterjee, Ian Martins, Simon M. Laws, Ashley I. Bush, Christopher C. Rowe, Victor L. Villemagne, David Ames, Colin L. Masters, Matthias Arnold, Gabi Kastenmüller, Kwangsik Nho, Andrew J. Saykin, Rebecca Baillie, Xianlin Han, Ralph N. Martins, Eric Moses, Rima F. Kaddurah‐Daouk, and Peter J Meikle

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2021

15. Decrease in p3‐Alcβ37 and p3‐Alcβ40, products of Alcadein β generated by γ‐secretase cleavages, in aged monkeys and patients with Alzheimer's disease

Author

Tadashi Nakaya, Christopher C. Rowe, Steve Pedrini, Masaaki Waragai, Kevin Taddei, Laurent Meijer, Nobuyuki Kimura, Ayano Kimura, Anqi Hu, Eugene Hone, Saori Hata, Haruka Saito, David Ames, Takeshi Ikeuchi, Ralph N. Martins, Masaki Nishimura, Colin L. Masters, Kazuo Yamamoto, Veer Bala Gupta, Sam Gandy, Chiori Omori, Toshiharu Suzuki, Pratishtha Chatterjee, Tohru Yamamoto, Kensaku Kasuga, and Masahiro Maeda

Subjects
0301 basic medicine, Drug, medicine.medical_specialty, media_common.quotation_subject, Cell, γ-secretase, Gene mutation, Cleavage (embryo), Presenilin, Pathogenesis, 03 medical and health sciences, 0302 clinical medicine, Cerebrospinal fluid, Internal medicine, medicine, Aftin-5, Protein precursor, media_common, Chemistry, Featured Article, Alzheimer's disease, Alcadein, p3-Alc, Psychiatry and Mental health, 030104 developmental biology, Endocrinology, medicine.anatomical_structure, Amyloid β-peptide, Neurology (clinical), Calsyntenin, 030217 neurology & neurosurgery
Abstract

Introduction Neuronal p3-Alcβ peptides are generated from the precursor protein Alcadein β (Alcβ) through cleavage by α- and γ-secretases of the amyloid β (Aβ) protein precursor (APP). To reveal whether p3-Alcβ is involved in Alzheimer's disease (AD) contributes for the development of novel therapy and/or drug targets. Methods We developed new sandwich enzyme-linked immunosorbent assay (sELISA) systems to quantitate levels of p3-Alcβ in the cerebrospinal fluid (CSF). Results In monkeys, CSF p3-Alcβ decreases with age, and the aging is also accompanied by decreased brain expression of Alcβ. In humans, CSF p3-Alcβ levels decrease to a greater extent in those with AD than in age-matched controls. Subjects carrying presenilin gene mutations show a significantly lower CSF p3-Alcβ level. A cell study with an inverse modulator of γ-secretase remarkably reduces the generation of p3-Alcβ37 while increasing the production of Aβ42. Discussion Aging decreases the generation of p3-Alcβ, and further significant decrease of p3-Alcβ caused by aberrant γ-secretase activity may accelerate pathogenesis in AD.

Published
2019

16. Identification of concordant plasma lipid signatures in Alzheimer’s disease: Validation between two independent studies of Alzheimer’s disease

Author

Adam Alexander T. Smith, Kaushala S. Jayawardana, Matthias Arnold, Ashley I. Bush, Gavriel Olshansky, Xianlin Han, David Ames, Ian Martins, Agus Salim, Simon M. Laws, Kevin Huynh, Victor L. Villemagne, Corey Giles, Christopher C. Rowe, Kwangsik Nho, Rebecca Baillie, Andrew J. Saykin, Rima Kaddurah-Daouk, Brian G. Drew, Wei Ling Florence Lim, Pratishtha Chatterjee, Colin L. Masters, Ralph N. Martins, Natalie A. Mellett, and Peter J. Meikle

Subjects
Epidemiology, business.industry, Health Policy, Computational biology, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Lipidomics, Plasma lipids, Medicine, Identification (biology), Neurology (clinical), Geriatrics and Gerontology, business
Published
2020

17. Improved centiloid robustness using non‐negative matrix factorization

Author

Christopher C. Rowe, Victor L. Villemagne, Vincent Dore, David Ames, Jurgen Fripp, Pierrick Bourgeat, Ralph N. Martins, and Colin L. Masters

Subjects
Epidemiology, Computer science, business.industry, Health Policy, Disease progression, Pattern recognition, Tracking (particle physics), Non-negative matrix factorization, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, Robustness (computer science), Neurology (clinical), Artificial intelligence, Geriatrics and Gerontology, business
Published
2020

18. Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease

Author

Petra L. Graham, Ashley I. Bush, Kaj Blennow, Colin L. Masters, Veer Bala Gupta, Christopher Fowler, Qiao-Xin Li, Henrik Zetterberg, Steven J. Collins, Victor L. Villemagne, Pierrick Bourgeat, Kunal Dhiman, David Ames, Ralph N. Martins, Dhamidhu Eratne, and Christopher C. Rowe

Subjects
Epidemiology, business.industry, Health Policy, Alzheimer's disease biomarkers, Cognition, medicine.disease, Synaptic protein, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Atrophy, Developmental Neuroscience, Neuroimaging, medicine, Neurology (clinical), Tauopathy, Geriatrics and Gerontology, Differential diagnosis, business, Neuroscience
Published
2020

19. Deficits in learning are greater than memory dysfunction in preclinical Alzheimer’s disease

Author

Andrea Mills, David Ames, Jenalle E. Baker, Stephanie R. Rainey-Smith, Loren Bruns, Colin L. Masters, Jurgen Fripp, Christopher Fowler, Yen Ying Lim, and Paul Maruff

Subjects
Memory Dysfunction, Epidemiology, business.industry, Health Policy, Neuropsychology, Cognition, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Clinical psychology
Published
2020

20. Genome‐wide study of the human lipidome and links to Alzheimer’s disease risk

Author

Natalie A. Mellett, Matthias Arnold, Peter J. Meikle, Rebecca Baillie, Adam Alexander T. Smith, Eric Moses, Rima Kaddurah-Daouk, Corey Giles, Gavriel Olshansky, Andrew J. Saykin, David Ames, Victor L. Villemagne, Ian Martins, Ashley I. Bush, Kevin Huynh, Xianlin Han, Michael Inouye, Gemma Cadby, Gabi Kastenmüller, Anh Nguyen, Christopher C. Rowe, Kwangsik Nho, Simon M. Laws, Colin L. Masters, Ralph N. Martins, and Pratishtha Chatterjee

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Disease risk, Neurology (clinical), Computational biology, Geriatrics and Gerontology, Lipidome, Biology, Genome
Published
2020

21. Comparison of peer mentoring versus peer support in a 6‐month home‐based physical activity program for inactive older adults at risk of Alzheimer’s disease: Experiences from the INDIGO trial

Author

Elizabeth V. Cyarto, Jennifer Southam, Nicola T. Lautenschlager, Kay L. Cox, Christopher Etherton-Beer, Dina LoGiudice, Danny Liew, Linda Clare, Osvaldo P. Almeida, Kathryn A. Ellis, David Ames, and Leon Flicker

Subjects
Gerontology, Epidemiology, Health Policy, Physical activity, Disease, Peer support, Home based, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Peer mentoring, Neurology (clinical), Geriatrics and Gerontology, Psychology
Published
2020

22. The association between mesial temporal tau with age, cognition and neocortical tau in Aβ cognitively unimpaired individuals using MK‐6240

Author

David Ames, Pierrick Bourgeat, Victor L. Villemagne, Anita M.Y. Goh, Colin L. Masters, Vincent Dore, Natasha Krishnadas, Kun Huang, Ralph N. Martins, Jurgen Fripp, Samantha C. Burnham, Paul Maruff, Colin Groot, and Christopher C. Rowe

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Cognition, Neurology (clinical), Geriatrics and Gerontology, Biology, Association (psychology), Neuroscience
Published
2020

23. Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study

Author

Irina Esterlis, Yen Ying Lim, Simon M. Laws, Olivier Salvado, Christopher C. Rowe, Victor L. Villemagne, Carolyn M. Mazure, Kathryn A. Ellis, Vincent Dore, Ralph N. Martins, Sophie E. Holmes, David Ames, Colin L. Masters, Robert H. Pietrzak, Paul Maruff, Christopher Fowler, and Stephanie R. Rainey-Smith

Subjects
Geriatrics, medicine.medical_specialty, 030214 geriatrics, Disease, Late life depression, 03 medical and health sciences, Psychiatry and Mental health, 0302 clinical medicine, Relative risk, medicine, Anxiety, Effects of sleep deprivation on cognitive performance, Geriatrics and Gerontology, medicine.symptom, Prospective cohort study, Psychology, Psychiatry, 030217 neurology & neurosurgery, Depression (differential diagnoses)
Abstract

Objective Depressive and anxiety symptoms are common in older adults, significantly affect quality of life, and are risk factors for Alzheimer's disease. We sought to identify the determinants of predominant trajectories of depressive and anxiety symptoms in cognitively normal older adults. Method Four hundred twenty-three older adults recruited from the general community underwent Aβ positron emission tomography imaging, apolipoprotein and brain-derived neurotrophic factor genotyping, and cognitive testing at baseline and had follow-up assessments. All participants were cognitively normal and free of clinical depression at baseline. Latent growth mixture modeling was used to identify predominant trajectories of subthreshold depressive and anxiety symptoms over 6 years. Binary logistic regression analysis was used to identify baseline predictors of symptomatic depressive and anxiety trajectories. Results Latent growth mixture modeling revealed two predominant trajectories of depressive and anxiety symptoms: a chronically elevated trajectory and a low, stable symptom trajectory, with almost one in five participants falling into the elevated trajectory groups. Male sex (relative risk ratio (RRR) = 3.23), lower attentional function (RRR = 1.90), and carriage of the brain-derived neurotrophic factor Val66Met allele in women (RRR = 2.70) were associated with increased risk for chronically elevated depressive symptom trajectory. Carriage of the apolipoprotein epsilon 4 allele (RRR = 1.92) and lower executive function in women (RRR = 1.74) were associated with chronically elevated anxiety symptom trajectory. Conclusion Our results indicate distinct and sex-specific risk factors linked to depressive and anxiety trajectories, which may help inform risk stratification and management of these symptoms in older adults at risk for Alzheimer's disease. Copyright © 2017 John Wiley & Sons, Ltd.

Published
2017

24. Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness

Author

Paul Maruff, Yen Ying Lim, Jason Hassenstab, Christopher C. Rowe, Simon M. Laws, Stephanie R. Rainey-Smith, Olivier Salvado, Karra Harrington, Joanne Robertson, Victor L. Villemagne, Peter J. Snyder, Ralph N. Martins, Vincent Dore, Colin L. Masters, and David Ames

Subjects
Amyloid, medicine.medical_specialty, lcsh:Geriatrics, Verbal learning, lcsh:RC346-429, 050105 experimental psychology, Developmental psychology, Cognitive aging, 03 medical and health sciences, 0302 clinical medicine, Memory, Internal medicine, medicine, Dementia, 0501 psychology and cognitive sciences, Cognitive decline, Episodic memory, lcsh:Neurology. Diseases of the nervous system, business.industry, Normal aging, 05 social sciences, Cognition, Clinical disease, medicine.disease, lcsh:RC952-954.6, Psychiatry and Mental health, Cognitive & Behavioral Assessment, Neurology (clinical), Alzheimer disease, Alzheimer's disease, business, 030217 neurology & neurosurgery
Abstract

Introduction High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aβ−) and high (Aβ+) CN older adults ( n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aβ− group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.

Published
2017

25. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging

Author

David Ames, Christopher C. Rowe, Colin L. Masters, S L Macaulay, Simon M. Laws, Veer Bala Gupta, Victor L. Villemagne, Alan Rembach, Eugene Hone, Stephanie R. Rainey-Smith, Ralph N. Martins, Ashley I. Bush, Madhav Thambisetty, James D. Doecke, and Steve Pedrini

Subjects
Brain amyloid beta, 0301 basic medicine, Oncology, Pathology, medicine.medical_specialty, Disease status, Early detection, Disease, lcsh:Geriatrics, lcsh:RC346-429, Pathogenesis, Plasma, 03 medical and health sciences, 0302 clinical medicine, Hippocampus volume, Internal medicine, medicine, lcsh:Neurology. Diseases of the nervous system, Clusterin, biology, business.industry, Blood-Based Biomarkers, 3. Good health, lcsh:RC952-954.6, Psychiatry and Mental health, 030104 developmental biology, Apolipoprotein J, Potential biomarkers, biology.protein, Biomarker (medicine), Neurology (clinical), business, Biomarkers, 030217 neurology & neurosurgery
Abstract

Introduction For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD. Methods Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele status, mini‐mental state examination score, plasma amyloid beta (Aβ), neocortical Aβ burden (as measured by Pittsburgh compound B‐positron emission tomography), and total adjusted hippocampus volume. Results ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as compared with healthy controls (HC; P

Published
2015

26. P1‐142: PERIPHERAL INFLAMMATORY BURDEN BIOMARKERS MODULATE THE RISK FOR ALZHEIMER'S DISEASE THROUGH KEY AD‐RELATED SNPS

Author

Paul Maruff, James D. Doecke, Ralph N. Martins, David Ames, Christopher C. Rowe, Simon M. Laws, Stephanie R. Rainey-Smith, Tenielle Porter, Samantha L. Gardener, Colin L. Masters, and Olivier Salvado

Subjects
Epidemiology, business.industry, Health Policy, Single-nucleotide polymorphism, Disease, Bioinformatics, Peripheral, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Key (cryptography), Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

27. P2‐415: QUANTITATIVE NORMALISED SODIUM MRI SIGNAL INTENSITY IS NOT ASSOCIATED WITH AGE IN COGNITIVELY NORMAL OLDER ADULTS: A 3 TESLA STUDY

Author

Christopher Steward, Patricia Desmond, David Ames, Elizabeth V. Cyarto, Nicola T. Lautenschlager, Kathryn A. Ellis, Chris Kokkinos, Vijay K. Venkatraman, Kay L. Cox, Elaine Liu, Tie-Qiang Li, Brad Sutton, Bradford A. Moffat, and Scott C Kolbe

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, Sodium MRI, Medicine, Neurology (clinical), Geriatrics and Gerontology, Signal intensity, business, Nuclear medicine
Published
2018

28. IC‐P‐008: VISUAL ASSESSMENT OF β‐AMYLOID PET SCAN IS IMPROVED BY CAPAIBL

Author

Victor L. Villemagne, Jurgen Fripp, John R. Hodges, Vincent Dore, Scott Williams, Claire E. Shepherd, Parnesh Raniga, Cristian E. Leyton, Colin L. Masters, Olivier Salvado, Ralph N. Martins, Christopher C. Rowe, Pierrick Bourgeat, Catriona MacLean, David Ames, Fairlie Hinton, Glenda M. Halliday, Sanka Amadoru, and Tia Cummins

Subjects
Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, β amyloid, Visual assessment, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

29. O2‐15‐03: DIFFERENTIAL RISK FACTORS FOR PROGRESSION TO MCI/DEMENTIA BY AMYLOID‐BETA STATUS

Author

Yen Ying Lim, Christa Dang, Nawaf Yassi, Christopher C. Rowe, Colin L. Masters, Victor L. Villemagne, Paul Maruff, Martha Hickey, Karra Harrington, and David Ames

Subjects
Oncology, medicine.medical_specialty, biology, Epidemiology, Amyloid beta, business.industry, Health Policy, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, medicine, biology.protein, Dementia, Neurology (clinical), Geriatrics and Gerontology, business, Differential (mathematics)
Published
2018

30. P4‐112: VERBAL LEARNING AND BETA‐AMYLOID: REPEATED ADMINISTRATION OF THE INTERNATIONAL SHOPPING LIST TEST

Author

Victor L. Villemagne, Jenalle E. Baker, Paul Maruff, Peter J. Snyder, Robert H. Pietrzak, Christopher C. Rowe, David Ames, Yen Ying Lim, Judith Jaeger, and Colin L. Masters

Subjects
Amyloid, Epidemiology, business.industry, Health Policy, Verbal learning, Test (assessment), Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Beta (finance), Administration (government), Shopping list, Clinical psychology
Published
2018

31. P1‐405: VISUAL ASSESSMENT OF β‐AMYLOID PET SCAN IS IMPROVED BY CAPAIBL

Author

Vincent Dore, Pierrick Bourgeat, Tia L. Cummins, Parnesh Raniga, Scott Williams, Sanka Amadoru, Catriona MacLean, Fairlie Hinton, Claire Shepherd, Glenda M. Halliday, Cristian E. Leyton, John R. Hodges, David Ames, Ralph N. Martins, Colin L. Masters, Jurgen Fripp, Olivier Salvado, Victor L. Villemagne, and Christopher Rowe

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2018

32. P1‐440: INCREASED CEREBRAL BLOOD FLOW WITH INCREASED AMYLOID BURDEN IN PRECLINICAL AD

Author

Lifestyle (Aibl), David Ames, Jurgen Fripp, Olivier Salvado, Xiaoyun Liang, Alan Connelly, Fernando Calamante, Vincent Dore, Christopher C. Rowe, Pierrick Bourgeat, Victor L. Villemagne, Parnesh Raniga, Amir Fazlollahi, and Colin L. Masters

Subjects
Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Cerebral blood flow, Medicine, Amyloid burden, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

33. O1‐04‐01: PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY

Author

Jenalle E. Baker, Victor L. Villemagne, David Ames, Loren Bruns, Yen Ying Lim, Paul Maruff, Jason Hassenstab, Stephanie R. Rainey-Smith, Colin L. Masters, Christopher C. Rowe, and Christopher Fowler

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Physical medicine and rehabilitation, Developmental Neuroscience, medicine, Neurology (clinical), Cognitive Assessment System, Geriatrics and Gerontology, business
Published
2018

34. O4‐06‐01: GENETIC VARIATION IN AQUAPORINS MODERATES THE RELATIONSHIP BETWEEN SLEEP AND BRAIN Aβ‐AMYLOID BURDEN

Author

Tenielle Porter, Christopher C. Rowe, Victor L. Villemagne, Hamid R. Sohrabi, Colin L. Masters, Lidija Milicic, Paul Maruff, Olivier Salvado, Gavin Noel Mazzucchelli, Stephanie R. Rainey-Smith, Ralph N. Martins, Kevin Taddei, Michael Weinborn, Simon M. Laws, Belinda M. Brown, David Ames, and Romola S. Bucks

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Genetic variation, Aquaporin, Aβ amyloid, Neurology (clinical), Geriatrics and Gerontology, Biology, Sleep in non-human animals, Neuroscience
Published
2018

35. O4‐09‐01: COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL Aβ‐AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD

Author

Christopher C. Rowe, Reisa A. Sperling, Vincent Dore, Pierrick Bourgeat, Olivier Salvado, Paul Maruff, Samantha C. Burnham, Victor L. Villemagne, Ralph N. Martins, Simon M. Laws, Colin L. Masters, David Ames, Greg Savage, and Charley Ann Budgeon

Subjects
Natural history, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Chemistry, Health Policy, Hippocampal volume, Aβ amyloid, Neurology (clinical), Geriatrics and Gerontology, Neuroscience
Published
2018

36. P1‐006: EXAMINING THE RESILIENCE OF SUPERAGERS: RISK OF CLINICAL PROGRESSION AND Aβ‐ASSOCIATED MEMORY DECLINE OVER 8 YEARS

Author

Karra Harrington, Martha Hickey, David Ames, Victor L. Villemagne, Yen Ying Lim, Christopher C. Rowe, Christa Dang, Nawaf Yassi, Colin L. Masters, and Paul Maruff

Subjects
Gerontology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, Medicine, Neurology (clinical), Geriatrics and Gerontology, Resilience (network), business, Clinical progression
Published
2018

37. IC‐06‐01: QUANTITATIVE SODIUM MRI IS MORE SENSITIVE THAN VOLUMETRY FOR DIFFERENTIATING BETWEEN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT AND THOSE WHO ARE COGNITIVELY NORMAL

Author

David Ames, Kay L. Cox, Elaine Liu, Nicola T. Lautenschlager, Scott C Kolbe, Christopher Steward, Vijay K. Venkatraman, Elizabeth V. Cyarto, Patricia Desmond, Kathryn A. Ellis, Chris Kokkinos, Tie-Qiang Li, Brad Sutton, and Bradford A. Moffat

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Audiology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Sodium MRI, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Cognitive impairment
Published
2018

38. P3‐470: PAIRED ASSOCIATE LEARNING DEFICITS ASSOCIATED WITH ELEVATED BETA‐AMYLOID IN COGNITIVELY NORMAL OLDER ADULTS

Author

Peter J. Snyder, Victor L. Villemagne, Robert H. Pietrzak, Christopher C. Rowe, Yen Ying Lim, Jenalle E. Baker, David Ames, Paul Maruff, Judith Jaeger, and Colin L. Masters

Subjects
medicine.medical_specialty, Amyloid, Epidemiology, business.industry, Health Policy, Paired associate learning, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Endocrinology, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, Beta (finance), business
Published
2018

39. P1‐636: DOES MENTOR‐SUPPORTED GOAL‐SETTING ENHANCE ADHERENCE TO A 6‐MONTH PHYSICAL ACTIVITY PROGRAM, IMPROVE PHYSICAL ACTIVITY AND FITNESS FOR INACTIVE OLDER ADULTS AT RISK OF ALZHEIMER'S DISEASE? THE INDIGO TRIAL

Author

Christopher Etherton-Beer, Kay L. Cox, Elizabeth V. Cyarto, Osvaldo P. Almeida, Dina LoGiudice, Linda Clare, Helman Alfonso, Kathryn A. Ellis, Danny Liew, Jennifer Southam, Nicola T. Lautenschlager, L. Flicker, and David Ames

Subjects
Gerontology, Epidemiology, business.industry, Health Policy, Physical activity, Disease, Indigo, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Goal setting
Published
2018

40. P3‐620: INCREASED PROTEIN AND FIBRE INTAKE IS ASSOCIATED WITH HIGHER PERFORMANCE IN THE AIBL PACC SCORE IN COGNITIVELY NORMAL ADULTS: AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE (AIBL) STUDY

Author

Victor L. Villemagne, Greg Savage, James D. Doecke, Paul Maruff, Colin L. Masters, Olivier Salvado, David Ames, Samantha C. Burnham, Warnakulasuriya M. A. D. B. Fernando, Michael Weinborn, Ralph N. Martins, Samantha L. Gardener, Biomarker Australian Imaging, Hamid R. Sohrabi, Stephanie R. Rainey-Smith, and Christopher C. Rowe

Subjects
Oncology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, medicine.medical_specialty, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

41. O3‐07‐06: IMPROVEMENTS IN SUBTHRESHOLD ANXIETY AND DEPRESSION SYMPTOMS IN OLDER, SEDENTARY ADULTS AT RISK OF ALZHEIMER'S DISEASE WHO ENGAGE IN A PHYSICAL ACTIVITY INTERVENTION

Author

Kay L. Cox, Danny Liew, Kathryn A. Ellis, Christopher Etherton-Beer, David Ames, Nicola T. Lautenschlager, Dina LoGiudice, Emily You, Linda Clare, Osvaldo P. Almeida, Helman Alfonso, Elizabeth V. Cyarto, and L. Flicker

Subjects
Epidemiology, business.industry, Subthreshold conduction, Health Policy, Physical activity, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Intervention (counseling), Medicine, Anxiety, Neurology (clinical), Geriatrics and Gerontology, medicine.symptom, business, Depression (differential diagnoses), Clinical psychology
Published
2018

42. P2‐634: CHANGES IN PHYSICAL ACTIVITY, GOAL‐SETTING SATISFACTION AND PERFORMANCE WITH A SIX‐MONTH, HOME‐BASED, PHYSICAL ACTIVITY PROGRAM IN INACTIVE OLDER ADULTS AT RISK OF ALZHEIMER'S DISEASE: THE INDIGO TRIAL

Author

Kay L. Cox, Danny Liew, Christopher Etherton-Beer, David Ames, Helman Alfonso, Linda Clare, Kathryn A. Ellis, L. Flicker, Dina LoGiudice, Jennifer Southam, Nicola T. Lautenschlager, Elizabeth V. Cyarto, and Osvaldo P. Almeida

Subjects
Gerontology, Epidemiology, business.industry, Health Policy, Physical activity, Disease, Home based, Indigo, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Goal setting
Published
2018

43. F3-04-03: STAKEHOLDER PERSPECTIVES ON HOW THE HOME CARE SECTOR CAN SUPPORT PEOPLE TO LIVE WELL WITH DEMENTIA

Author

Frances Batchelor, Colleen Doyle, Philip Clarke, Samantha M Loi, Lee-Fay Low, Jason Burton, Anita M.Y. Goh, Constantine G. Lyketsos, Steven Savvas, Ellen Gaffy, Luke Gahan, Gill Livingston, Margaret Winbolt, David Ames, Brendan Hallam, Briony Dow, Samuel C Scherer, Meg Polacsek, Claudia Cooper, Sue Malta, and Anita Panayiotou

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Nursing, Epidemiology, Health Policy, Stakeholder, medicine, Dementia, Neurology (clinical), Business, Geriatrics and Gerontology, medicine.disease
Published
2019

44. P2-581: THE SUPPORT PERSON'S PREFERENCES AND PERSPECTIVES OF PHYSICAL ACTIVITY FOR OLDER ADULTS WITH COGNITIVE IMPAIRMENT

Author

Nicola T. Lautenschlager, David Ames, Terence W.H. Chong, Kay L. Cox, Stephanie R. Rainey-Smith, Karra Harrington, Emily You, and Kathryn A. Ellis

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Physical activity, Support person, Neurology (clinical), Geriatrics and Gerontology, Cognitive impairment, Psychology, Clinical psychology
Published
2019

45. IC-P-167: AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON BRAIN SURFACE

Author

Victor L. Villemagne, David Ames, Samantha C. Burnham, Jurgen Fripp, Vincent Dore, Pierrick Bourgeat, Ralph N. Martins, Christopher C. Rowe, Colin L. Masters, and Olivier Salvado

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Chemistry, Health Policy, Neurology (clinical), Brain surface, Geriatrics and Gerontology, Biomedical engineering
Published
2019

46. Factors associated with depression in older carers

Author

Nicola T. Lautenschlager, Briony Dow, David Ames, Sue Malta, Elizabeth V. Cyarto, Melissa Russell, Keith D. Hill, Kirsten Moore, and Samantha M Loi

Subjects
Gerontology, Population ageing, health care facilities, manpower, and services, media_common.quotation_subject, Psychological intervention, 03 medical and health sciences, 0302 clinical medicine, Medicine, Personality, 030212 general & internal medicine, Big Five personality traits, health care economics and organizations, Depression (differential diagnoses), media_common, business.industry, social sciences, Mental health, Neuroticism, humanities, Psychiatry and Mental health, Geriatric Depression Scale, Geriatrics and Gerontology, business, human activities, 030217 neurology & neurosurgery, Clinical psychology
Abstract

Objective Depression is an adverse outcome frequently seen in carers. With the increasing ageing population and reliance on informal carers, this study aims to identify factors associated with depression in carers in the older age group, using factors that have not been previously investigated. Methods We conducted a cross-sectional analysis of 202 older carers using the Geriatric Depression scale, demographics, personality traits, attitudes to ageing and other carer characteristics. Results Increased hours spent caring and higher levels of neuroticism were all factors associated with depression. The care-recipient diagnosis, other personality traits, attitudes to ageing, leisure-physical activity (PA) and domestic-PA were not significantly associated with depression. Conclusions These findings have important implications for interventions to target at-risk carers. Copyright © 2015 John Wiley & Sons, Ltd.

Published
2015

47. Semi-automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration

Author

Charles B Malpas, Pramit M. Phal, Elizabeth V. Cyarto, Bernd Merkel, Michelle Lai, Nicola T. Lautenschlager, Christopher Steward, Kathryn A. Ellis, Patricia Desmond, Lucy Vivash, David Ames, Matthew J. Sharman, Colin L. Masters, Cassandra Szoeke, Kay L. Cox, and Bradford A. Moffat

Subjects
Normalization (statistics), medicine.diagnostic_test, business.industry, Magnetic resonance imaging, Voxel-based morphometry, Subjective memory, Age appropriate, Hippocampal segmentation, Medicine, Radiology, Nuclear Medicine and imaging, Segmentation, business, Nuclear medicine, Cognitive impairment
Abstract

Background To evaluate a new semi-automated segmentation method for calculating hippocampal volumes and to compare results with standard software tools in a cohort of people with subjective memory complaints (SMC) and mild cognitive impairment (MCI). Methods Data from 58 participants, 39 with SMC (17 male, 22 female, mean age 72.6) and 19 with MCI (6 male, 13 female, mean age 74.3), were analyzed. For each participant, T1-weighted images were acquired using an MPRAGE sequence on a 3 Tesla MRI system. Hippocampal volumes (left, right, and total) were calculated with a new, age appropriate registration template, based on older people and using the advanced software tool ANTs (Advanced Normalization Tools). The results were compared with manual tracing (seen as the reference standard) and two widely accepted automated software tools (FSL, FreeSurfer). Results The hippocampal volumes, calculated by using the age appropriate registration template were significantly (P

Published
2015

48. [IC‐P‐158]: IMPLEMENTING THE CENTILOID TRANSFORMATION FOR 18 F‐FLORBETABEN AND 18 F‐NAV4694 USING CAPAIBL

Author

Jurgen Fripp, Pierrick Bourgeat, David Ames, Colin L. Masters, Vincent Dore, Olivier Salvado, Victor L. Villemagne, and Christopher C. Rowe

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Pure mathematics, Transformation (function), Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology, Florbetaben, Mathematics
Published
2017

49. [P4–499]: REFINING THE NATURAL HISTORY OF GLOBAL AND REGIONAL Aβ‐AMYLOID DEPOSITION IN SPORADIC ALZHEIMER's DISEASE

Author

Pierrick Bourgeat, Stephanie R. Rainey-Smith, Olivier Salvado, Greg Savage, Ralph N. Martins, Vincent Dore, Christopher C. Rowe, Paul Maruff, Colin L. Masters, Samantha C. Burnham, Simon M. Laws, Victor L. Villemagne, David Ames, and Belinda M. Brown

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Chemistry, Refining, Health Policy, Environmental chemistry, Aβ amyloid, Neurology (clinical), Geriatrics and Gerontology, Deposition (chemistry)
Published
2017

50. [O4–04–06]: VASCULAR RISK MEASURES AND LONGITUDINAL Aβ ACCUMULATION: RESULTS FROM THE AIBL STUDY OF AGEING

Author

Victor L. Villemagne, Paul Yates, Christopher C. Rowe, David Ames, Olivier Salvado, Ralph N. Martins, Samantha C. Burnham, Stephanie R. Rainey-Smith, Colin L. Masters, and Vincent Dore

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Vascular risk, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Ageing, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results